Icotinib versus chemotherapy as adjuvant treatment for stage II–IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trialJianxing He, Caicun Zhou, Weimin Mao et al.|The Lancet Respiratory Medicine|2021Cited by 183
let‑7 and miR‑17 promote self‑renewal and drive gefitinib resistance in non‑small cell lung cancerJun Yin, Jian Zhao|Oncology Reports|2019Cited by 28
Expert consensus on treatment for stage III non‐small cell lung cancerYi‐Long Wu, Yun Fan, Shun Lü et al.|Medicine Advances|2023Cited by 18
CIAdex: Single-Cell FTIR Spectral Fingerprinting for Cell Identity Verification and Aging Quantification in Therapeutic Cell ManufacturingWang Ying, Jian Zhao|bioRxiv (Cold Spring Harbor Laboratory)|2025Cited by 0